Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$4.29M+81.3%-$22.96M-111%-$10.85M-11.4%-$9.74M-46.0%-$6.67M+80.1%
$631K+12.1%$563K-3.6%$584K+4.5%$559K+15.5%$484K-10.5%
$615K-14.7%$721K+38.4%$521K+3.4%$504K+6.6%$473K-5.2%
-$7.64M-37.8%-$5.55M-23.2%-$4.5M+28.5%-$6.3M-7.9%-$5.84M-9.1%
$613K-58.6%$1.48M+40.9%$1.05M+201%$349K+13.7%$307K+43.5%
-$613K+58.6%-$1.48M-40.9%-$1.05M-201%-$349K-13.7%-$307K-46.2%
$24.7M$28.56M+164%
$16.44M$22.39M
-$8.25M-17.5%-$7.02M-26.5%-$5.55M+16.5%-$6.65M-8.2%-$6.15M-10.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Insight Molecular Diagnostics Inc. Common Stock generate?
Insight Molecular Diagnostics Inc. Common Stock (IMDX) generated -$24.0M in operating cash flow over the trailing twelve months.
What is Insight Molecular Diagnostics Inc. Common Stock's free cash flow?
After $3.5M of capital expenditures, Insight Molecular Diagnostics Inc. Common Stock's free cash flow was -$27.5M over the trailing twelve months, down 16.9% year over year.
Where does Insight Molecular Diagnostics Inc. Common Stock's cash flow data come from?
Every line is extracted from Insight Molecular Diagnostics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.